SAHPRA green light for Covid treatment pill
The South African Health Products Regulatory Authority has authorised the use of the Covid-19 treatment pill molnupiravir.
It is only authorized for use in patients aged 18 years and older.
In a statement released on Thursday, SAHPRA CEO Boitumelo Semete-Makokotlela said the authorisation is initially limited to six months.
The medication will require a prescription and is not recommended during pregnancy.
“The authorisation of molnupiravir for compassionate use offers further therapy in the fight against COVID-19. SAHPRA will continue to play its part in ensuring the quality, safety and efficacy of all health products, including innovative treatments so that the public is protected at all times,” said Semete-Makokotlela.
ALSO READ
